Recent studies have demonstrated that anti-PD-L1 antibody induced durable tumor regression and prolonged stabilization of disease in patients with advanced cancer, including non-small cell lung cancer (NSCLC), melanoma, and colorectal cancer [54]. Here, CD274 is linked to non-small cell lung carcinoma.